13F HOLDINGS REPORT
SR ONE CAPITAL MANAGEMENT, LP
Quarter ended Q2 2024 · Filed August 13, 2024 · Accession 0000950123-24-008225
Total Value
$319.4M
Positions
9
Other Managers
0
Confidential Omitted
No
Holdings (9)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Arcellx, Inc. | ACLX | 2,346,630 | $129.5M | 40.55% |
| 2 | CRISPR Therapeutics AG | CRSP | 1,048,951 | $56.7M | 17.74% |
| 3 | ARS Pharmaceuticals, Inc. | SPRY | 4,012,903 | $34.1M | 10.69% |
| 4 | Alumis Inc. | ALMS | 1,959,896 | $26.1M | 8.16% |
| 5 | Mineralys Therapeutics Inc. | MLYS | 2,016,822 | $23.6M | 7.39% |
| 6 | Design Therapeutics, Inc. | DSGN | 6,526,476 | $21.9M | 6.85% |
| 7 | Nkarta, Inc. | NKTX | 3,333,333 | $19.7M | 6.17% |
| 8 | enGene Holdings Inc. | ENGNW | 500,000 | $4.7M | 1.48% |
| 9 | KALA Bio, Inc. | KALA | 443,661 | $3.1M | 0.98% |